Neurogene Inc. Proceeds from (Repayments of) Debt
Neurogene Inc. (NGNE) reported Proceeds from (Repayments of) Debt of -$2.60 million for the 12-month period ending 2014-12-31, per its 10-K filed 2017-03-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfDebt · last filed 2017-03-09
- Neurogene Inc. proceeds from (repayments of) debt for fiscal 2014 was -$2.60M, a 208.70% decline from fiscal 2013.
- Neurogene Inc. proceeds from (repayments of) debt for fiscal 2013 was $2.39M.
| Period end | Proceeds from (Repayments of) Debt 12 month | Proceeds from (Repayments of) Debt 12 month as first filed |
|---|---|---|
| 2014-12-31 | -$2.60M 10-K · filed 2017-03-09 | -$2.50M 10-K · filed 2015-03-16 |
| 2013-12-31 | $2.39M 10-K · filed 2016-03-14 | $2.50M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |